Arcus Biosciences (RCUS) revenue breakdown
By product, License and development services is the largest at 89% of fiscal 2025 revenue, growing 44% a year over 3 years.
Revenue by product
Fiscal years, as Arcus Biosciences reports them in its 10-K filings; fiscal 2025 total $247M.
| Products | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| License and development services | — | — | — | — | $74M | $80M | $222M | $221M | 89% |
| Other Collaboration Revenue | — | — | — | — | $38M | $37M | $36M | $26M | 11% |
| License to domvanalimab | — | — | — | $329M | — | — | — | — | — |
| Gilead Collaboration, License to Zimberelimab | — | — | $55M | — | — | — | — | — | — |
| Access rights | — | — | $16M | $31M | — | — | — | — | — |
| License to domvanalimab | — | — | — | $15M | — | — | — | — | — |
| Taiho License to Zimberelimab | — | $8M | — | — | — | — | — | — | — |
| Access rights | $5M | $7M | $7M | $7M | — | — | — | — | — |
| Taiho License to Etrumadenant | $3M | — | — | — | — | — | — | — | — |
| License and R&D services | — | — | — | $1M | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for RCUS.
Open RCUS in InvestinglyQuestions
Where does Arcus Biosciences make its money?
In fiscal 2025, by product: License and development services $221M, Other Collaboration Revenue $26M.
From Arcus Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.